Development and radiolabeling of lipid nanoparticles with [Tc-99m]Tc-HMPAO: Characterization, stability, cytotoxicity and cell binding studies

ATLIHAN GÜNDOĞDU E. , EKİNCİ M. , ÖZGENÇ E. , Demir E. S. , İLEM ÖZDEMİR D.

JOURNAL OF RESEARCH IN PHARMACY, vol.26, no.1, pp.88-101, 2022 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.29228/jrp.106
  • Title of Journal : JOURNAL OF RESEARCH IN PHARMACY
  • Page Numbers: pp.88-101
  • Keywords: Lipid nanoparticles, radiopharmaceuticals, HMPAO, cell binding, cancer diagnosis, CHITOSAN NANOPARTICLES, IN-VITRO, FORMULATION, CARRIERS

Abstract

In this study, we aimed to develop new lipid based nanoparticles (LPNs) and radiolabeled LPNs with [Tc-99m]Tc-HMPAO to investigate its cell binding capacity comparatively with [Tc-99m]Tc-HMPAO on different cancer cells. According to obtained results, LPNs with zeta potential of -27.4 +/- 0.95 mV, particle size of 93.5 +/- 1.17 nm, and polydispersity index of 0.35 +/- 0.04 were successfully developed. The optimum radiolabeling efficiency was found to be above 90% at 15-min of incubation time. The cell binding capacity of [Tc-99m]Tc-HMPAO-LPNs was found to be higher than [Tc-99m]Tc-HIYIPAO in cancer cell lines. The results demonstrated that [Tc-99m]Tc-HMPAO-LPNs may be a promising agent for cancer diagnosis alternatively to [Tc-99m]Tc-HMPAO.